Our annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
15 May 2018
In the version of this article initially published, the name and photo of Viviane Tabar, one of BlueRock's founders, was omitted. A misplaced '&' in the author list in the PDF has been corrected, and the abbreviation MSKCC added in the text. The errors have been corrected in the HTML and PDF versions of the article.
References
Garber, K. Natural killer cells blaze into immuno-oncology. Nat. Biotechnol. 34, 219–220 (2016).
Ardolino, M. et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J. Clin. Invest. 124, 4781–4794 (2014).
Deng, W. et al. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 348, 136–139 (2015).
Thompson, T.W. et al. Endothelial cells express NKG2D ligands and desensitize antitumor NK responses. eLife 6, e30881 (2017).
Matthews, M.L. et al. Chemoproteomic profiling and discovery of protein electrophiles in human cells. Nat. Chem. 9, 234–243 (2017).
Perni, M. et al. A natural product inhibits the initiation of a-synuclein aggregation and suppresses its toxicity. Proc. Natl. Acad. Sci. USA 114, E1009–E1017 (2017).
Robotta, M., Cattani, J., Martins, J.C., Subramaniam, V. & Drescher, M. Alpha-synuclein disease mutations are structurally defective and locally affect membrane binding. J. Am. Chem. Soc. 139, 4254–4257 (2017).
Svensson, E. et al. Vagotomy and subsequent risk of Parkinson's disease. Ann. Neurol. 78, 522–529 (2015).
Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547–551 (2011).
Chong, J.J. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273–277 (2014).
Shiba, Y. et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 538, 388–391 (2016).
Adler, A.S. et al. Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade, discovered using microfluidics and molecular genomics. MAbs 9, 1270–1281 (2017).
Adler, A.S. et al. Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics. MAbs 9, 1282–1296 (2017).
Sheridan, C. Recasting natural product research. Nat. Biotechnol. 30, 385–387 (2012).
Hart, T. et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515–1526 (2015).
Mateos-Gomez, P.A. et al. Mammalian polymerase q promotes alternative NHEJ and suppresses recombination. Nature 518, 254–257 (2015).
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
Zhou, Y. et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509, 487–491 (2014).
Zhu, S. et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat. Biotechnol. 34, 1279–1286 (2016).
Hartwell, L.H., Szankasi, P., Roberts, C.J., Murray, A.W. & Friend, S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064–1068 (1997).
Friend, S.H. & Oliff, A. Emerging uses for genomic information in drug discovery. N. Engl. J. Med. 338, 125–126 (1998).
Brockmann, M. et al. Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling. Nature 546, 307–311 (2017).
Carette, J.E. et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326, 1231–1235 (2009).
Chen, R. et al. Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nat. Biotechnol. 34, 531–538 (2016).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Branca, M., Garber, K. & DeFrancesco, L. Nature Biotechnology's academic spinouts of 2017. Nat Biotechnol 36, 297–306 (2018). https://doi.org/10.1038/nbt.4121
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4121